ScVEGF microbubble ultrasound contrast agents: A novel probe for ultrasound molecular imaging of tumor angiogenesis

Investigative Radiology

Volumn 45, Issue 10, 2010, Pages 579-585

  Anderson, Christopher R ^a   Rychak, Joshua J ^a   Backer, Marina ^b   Backer, Joseph ^b   Ley, Klaus ^c   Klibanov, Alexander L ^d  

^a Targeson Inc   (United States)

^b SIBTECH INC   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

single chain VEGF; targeted microbubbles; tumor angiogenesis imaging; ultrasound molecular imaging; VEGF receptors

Indexed keywords

AMINO ACID; CYSTEINE; DYE; ECHO CONTRAST MEDIUM; LIGAND; MALEIMIDE; RECOMBINANT SINGLE CHAIN VASCULAR ENDOTHELIAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON ADENOCARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CONJUGATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUOROMETRY; HUMAN; HUMAN CELL; MICROBUBBLE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULTRASOUND;

EID: 77957253179     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181efd581     Document Type: Article

References (44)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438: 932-936.
2. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1197-1202.
3. Plate KH, Breier G, Millauer B, et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 1993;53:5822-5827.
4. Itakura J, Ishiwata T, Shen B, et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer. 2000;85:27-34.
5. Koukourakis MI, Giatromanolaki A, Thorpe PE, et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 2000;60: 3088-3095.
6. Vajkoczy P, Farhadi M, Gaumann A, et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF recep-tor-2, and angiopoietin-2. J Clin Invest. 2002;109:777-785.
7. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-1027.
8. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999;59: 5209-5218.
9. Hess C, Vuong V, Hegyi I, et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer. 2001;85:2010-2016.
10. Bruns CJ, Shrader M, Harbison MT, et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopi-cally in nude mice. Int J Cancer. 2002;102:101-108.
11. Weber WA, Czernin J, Phelps ME, et al. Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol. 2008;5:44-54.
12. Cai W, Rao J, Gambhir SS, et al. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006;5:2624-2633.
13. Blankenberg FG, Backer MV, Levashova Z, et al. In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur JNucl Med Mol Imaging. 2006;33:841-848.
14. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med. 2006;47:2048-2056.
15. Korpanty G, Carbon JG, Grayburn PA, et al. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res. 2007;13:323-330.
16. Lee DJ, Lyshchik A, Huamani J, et al. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med. 2008;27:855-866.
17. Willmann JK, Paulmurugan R, Chen K, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology. 2008;246:508-518.
18. Rychak JJ, Graba J, Cheung AM, et al. Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Mol Imaging. 2007;6:289-296.
19. Klibanov AL. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol. 2006;41:354-362.
20. Lindner JR, Song J, Christiansen J, et al. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation. 2001;104:2107-2112.
21. Linker RA, Reinhardt M, Bendszus M, et al. In vivo molecular imaging of adhesion molecules in experimental autoimmune encephalomyelitis (EAE). J Autoimmun. 2005;25:199-205.
22. Weller GE, Lu E, Csikari MM, et al. Ultrasound imaging of acute cardiac transplant rejection with microbubbles targeted to intercellular adhesion molecule-1. Circulation. 2003;108:218-224.
23. Korpanty G, Grayburn PA, Shohet RV, et al. Targeting vascular endothelium with avidin microbubbles. Ultrasound Med Biol. 2005;31:1279-1283.
24. Pagenelli G, Chinol M, Maggiolo M, et al. The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur J Nucl Med. 1997;24:350-351.
25. Breitz HB, Weiden PL, Beaumier PL, et al. Clinical optimization of pretar-geted radioimmunotherapy with antibody streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med. 2000;41:131-140.
26. Backer MV, Gaynutdinov TI, Patel V, et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther. 2005;4:1423-1429.
27. Thirumamagal BT, Zhao XB, Bandyopadhyaya AK, et al. Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT). Bioconjug Chem. 2006;17:1141-1450.
28. Backer MV, Levashova Z, Patel V, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med. 2007;13:504-509.
29. Bachmann C, Klibanov AL, Olson TS, et al. Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn's disease. Gastroenterology. 2006;130:8-16.
30. Backer MV, Backer JM. Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. Bioconjug Chem. 2001;12:1066-1073.
31. Marsh JN, Partlow KC, Abendschein DR, et al. Molecular imaging with targeted perfluorocarbon nanoparticles: quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound Med Biol. 2007;33:950-958.
32. Backer MV, Patel V, Jehning BT, et al. Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. Biomateri-als. 2006;27:5452-5458.
33. Lanza GM, Wallace KD, Scott MJ, et al. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation. 1996;94: 3334-3340.
34. Kaufmann BA, Sanders JM, Davis C, et al. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation. 2007;116:276-284.
35. Ellegala DB, Leong-Poi H, Carpenter JE, et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha (v) beta3. Circulation. 2003;108:336-341.
36. Jun HY, Park SH, Kim HS, et al. Long residence time of ultrasound microbubbles targeted to integrin in murine tumor model. Acad Radiol. 2010;17:54-60.
37. Xuan JW, Bygrave M, Valiyeva F, et al. Molecular targeted enhanced ultrasound imaging of flk1 reveals diagnosis and prognosis potential in a genetically engineered mouse prostate cancer model. Mol Imaging. 2009;8: 209-220.
38. Willmann JK, Lutz AM, Paulmurugan R, et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology. 2008;248:936-944.
39. Weller GE, Wong MK, Modzelewski RA, et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res. 2005;65:533-539.
40. Dayton PA, Pearson D, Clark J, et al. Ultrasonic analysis of peptide-and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells. Mol Imaging. 2004;3:125-134.
41. Stieger SM, Dayton PA, Borden MA, et al. Imaging of angiogenesis using Cadence contrast pulse sequencing and targeted contrast agents. Contrast Media Mol Imaging. 2008;3:9-18.
42. Alon R, Bayer EA, Wilchek M. Cell-adhesive properties of streptavidin are mediated by the exposure of an RGD-like RYD site. Eur J Cell Biol. 1992;58:271-279.
43. Backer MV, Levashova Z, Levenson R, et al. Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins. Methods Mol Biol. 2008;494:275-294.
44. Lawrence MB, McIntire LV, Eskin SG. Effect of flow on polymorphonuclear leukocyte/endothelial cell adhesion. Blood. 1987;97:473-483.